Akèy › Maladi fwa steatotik › Virginia › Richmond
Etid klinik pou Maladi fwa steatotik nan Richmond, VA
12 etid pou Maladi fwa steatotik ap chèche patisipan nan sit nan ak bò kote Richmond (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
Ap rekriteFaz 3
- 89bio Clinical Study Site, Richmond
- 89bio Clinical Study Site, Richmond
- 89bio Clinical Study Site, Richmond
A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
Ap rekriteFaz 3
- 89bio Clinical Study Site, Richmond
- 89bio Clinical Study Site, Richmond
- 89bio Clinical Study Site, Richmond
Liver Cirrhosis Network Rosuvastatin Efficacy and Safety for Cirrhosis in the United States
Ap rekriteFaz 2
- Virginia Commonwealth University, Richmond
A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This Condition
Ap rekriteFaz 2
- Richmond Veterans Administration Medical Center, Richmond
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
Ap rekriteFaz 3
- Richmond Veterans Affairs Medical Center (Richmond VA Medical Center), Richmond
- Virginia Commonwealth University (VCU) Medical Center, Richmond
A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
Ap rekriteFaz 3
- Akero Clinical Study Site, Richmond
- Akero Clinical Study Site, Richmond
- Akero Clinical Study Site, Richmond
- ak 1 plis
A Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH)
Ap rekriteFaz 2
- GI Alliance Richmond, Richmond
- GI Select Health Research, Richmond
A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 70 Years With Alcohol-related Liver Disease
Ap rekriteFaz 2
- GSK Investigational Site, Richmond
- GSK Investigational Site, Richmond
A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASH
Ap rekriteFaz 2
- GSK Investigational Site, Richmond
Randomized Double Blinded Placebo-Controlled w/Semaglutide to Prevent Weight Gain After Liver Transplant
Ap rekriteFaz 2
- Virginia Commonwealth University, Richmond
Non-Invasive Quantification of Liver Health in NASH (N-QUAN)
Ap rekrite
- Virginia Common wealth University, Richmond
Predicting Outcomes in Nonalcoholic Steatohepatitis With Advanced Fibrosis
Ap rekriteEtid obsèvasyon
- Virginia Commonwealth University, Richmond
Etid Maladi fwa steatotik nan lòt vil
- San Antonio, TX17 etid
- New York City, NY16 etid
- Miami, FL16 etid
- San Diego, CA14 etid
- Austin, TX13 etid
- Houston, TX13 etid
- Tucson, AZ10 etid
- Chandler, AZ10 etid
- St. Louis, MO9 etid
- Hialeah, FL9 etid
- Dallas, TX9 etid
- Orlando, FL9 etid
Lòt etid nan Richmond
- Kansè nan tete26 etid
- Kansè Poumon ki pa ti selil25 etid
- Kansè pwostat19 etid
- Ensifizyans kadyak16 etid
- Kansè poumon14 etid
- Maladi kadyovaskilè13 etid
- Kansè kolorektal13 etid
- Leksemi mieloïd egi12 etid
- Kansè Metastatik12 etid
- Karsinòm selil skuamèz tèt ak kou12 etid
- Melanom11 etid
- Obèsite11 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.